1.Four Novel Synthetic Tryptamine Analogs Induce Head-Twitch Responses and Increase 5-HTR2a in the Prefrontal Cortex in Mice
Arvie ABIERO ; In Soo RYU ; Chrislean Jun BOTANAS ; Raly James Perez CUSTODIO ; Leandro Val SAYSON ; Mikyung KIM ; Hyun Jun LEE ; Hee Jin KIM ; Joung-Wook SEO ; Min Chang CHO ; Kun Won LEE ; Sung Yeun YOO ; Choon-Gon JANG ; Yong Sup LEE ; Jae Hoon CHEONG
Biomolecules & Therapeutics 2020;28(1):83-91
Tryptamines are monoamine alkaloids with hallucinogenic properties and are widely abused worldwide. To hasten the regulations of novel substances and predict their abuse potential, we designed and synthesized four novel synthetic tryptamine analogs: Pyrrolidino tryptamine hydrochloride (PYT HCl), Piperidino tryptamine hydrochloride (PIT HCl), N,N-dibutyl tryptamine hydrochloride (DBT HCl), and 2-Methyl tryptamine hydrochloride (2-MT HCl). Then, we evaluated their rewarding and reinforcing effects using the conditioned place preference (CPP) and self-administration (SA) paradigms. We conducted an open field test (OFT) to deter-mine the effects of the novel compounds on locomotor activity. A head-twitch response (HTR) was also performed to characterize their hallucinogenic properties. Lastly, we examined the effects of the compounds on 5-HTR1a and 5-HTR2a in the prefrontal cortex using a quantitative real-time polymerase chain reaction (qRT-PCR) assay. None of the compounds induced CPP in mice or initiated SA in rats. PYT HCl and PIT HCl reduced the locomotor activity and elevated the 5-HTR1a mRNA levels in mice. Acute and repeated treatment with the novel tryptamines elicited HTR in mice. Furthermore, a drug challenge involving a 7-day abstinence from drug use produced higher HTR than acute and repeated treatments. Both the acute treatment and drug challenge increased the 5-HTR2a mRNA levels. Ketanserin blocked the induced HTR. Taken together, the findings suggest that PYT HCl, PIT HCl, DBT HCl, and 2-MT HCl produce hallucinogenic effects via 5-HTR2a stimulation, but may have low abuse potential.
2.Postpartum Superior Sagittal Sinus Thrombosis: A Case Report.
Kun Hee HAN ; Yu Deok WON ; Min Kyun NA ; Myung Hoon HAN ; Je Il RYU ; Jae Min KIM ; Choong Hyun KIM ; Jin Hwan CHEONG
Korean Journal of Neurotrauma 2018;14(2):146-149
Cerebral venous sinus thrombosis (CVST) is a rare disease. Early diagnosis and treatment are important, as CVST is potentially fatal. Pregnancy and puerperium are known risk factors for CVST. Here, we report the case of a patient who developed superior sagittal sinus thrombosis after a normal vaginal delivery. A 20-year-old woman presented with a headache and seizures two days after a normal vaginal delivery. Initially, brain computed tomography (CT) showed a subarachnoid hemorrhage in the right parietal lobe and sylvian fissure, together with mild cerebral edema. CT angiography revealed superior sagittal sinus thrombosis. Multiple micro-infarctions were seen on diffusion-weighted magnetic resonance images. An intravenous infusion of heparin and mannitol was administered immediately. Two days after treatment initiation, the patient showed sudden neurological deterioration, with left-sided hemiplegia. Brain CT showed moderate brain edema and hemorrhagic densities. Emergency decompressive craniectomy was performed, and heparin was re-administered on post-operative day (POD) 1. On POD 9, the patient's mental state improved from stupor to drowsy, but the left-sided hemiplegia persisted. CT angiography showed that the superior sinus thrombosis had decreased. Superior sagittal sinus thrombosis is an uncommon complication, with an unfavorable outcome, after delivery. Timely diagnosis and treatment are important for preventing neurological deterioration.
Angiography
;
Brain
;
Brain Edema
;
Cerebral Infarction
;
Decompressive Craniectomy
;
Diagnosis
;
Early Diagnosis
;
Emergencies
;
Female
;
Headache
;
Hemiplegia
;
Heparin
;
Humans
;
Infusions, Intravenous
;
Mannitol
;
Parietal Lobe
;
Postpartum Period*
;
Pregnancy
;
Rare Diseases
;
Risk Factors
;
Seizures
;
Sinus Thrombosis, Intracranial
;
Stupor
;
Subarachnoid Hemorrhage
;
Superior Sagittal Sinus*
;
Thrombosis*
;
Young Adult
3.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
Li Tzong CHEN ; Do Youn OH ; Min Hee RYU ; Kun Huei YEH ; Winnie YEO ; Roberto CARLESI ; Rebecca CHENG ; Jongseok KIM ; Mauro ORLANDO ; Yoon Koo KANG
Cancer Research and Treatment 2017;49(4):851-868
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate that pharmacologic blockade of angiogenesis is a promising approach to therapy. In this systematic review, we summarize current literature on the clinical benefit of anti-angiogenic agents in advanced gastric cancer. We conducted a systematic search of PubMed and conference proceedings including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress. Included studies aimed to prospectively evaluate the efficacy and safety of anti-angiogenic agents in advanced gastric or gastroesophageal junction cancer. Each trial investigated at least one of the following endpoints: overall survival, progression-free survival/time to progression, and/or objective response rate. Our search yielded 139 publications. Forty-two met the predefined inclusion criteria. Included studies reported outcomes with apatinib, axitinib, bevacizumab, orantinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, telatinib, and vandetanib. Second-line therapy with ramucirumab and third-line therapy with apatinib are the only anti-angiogenic agents so far shown to significantly improve survival of patients with advanced gastric cancer. Overall, agents that specifically target the vascular endothelial growth factor ligand or receptor have better safety profile compared to multi-target tyrosine kinase inhibitors.
Angiogenesis Inhibitors
;
Bevacizumab
;
Disease-Free Survival
;
Esophagogastric Junction*
;
Humans
;
Medical Oncology
;
Neoplasm Metastasis
;
Prognosis
;
Prospective Studies
;
Protein-Tyrosine Kinases
;
Stomach Neoplasms
;
Vascular Endothelial Growth Factor A
;
Vascular Endothelial Growth Factors
4.Changes in Clinical Characteristics of the Patients Who Received Endoscopic Sinus Surgery according to 10 Year Temporal Difference: A Retrospective Observational Study.
In Yong RYU ; Chul KWON ; Tae Kyung KOH ; Kun Hee LEE ; Joong Saeng CHO ; Sung Wan KIM
Journal of Rhinology 2016;23(2):81-84
BACKGROUND AND OBJECTIVES: Endoscopic sinus surgery (ESS) was introduced to Korea in the 1980s and has since developed rapidly. There have been many changes in ESS over this period. Thus, in this paper, we explore trends in the clinical characteristics of ESS. SUBJECTS AND METHOD: We retrospectively reviewed patients who underwent the ESS at 000 Hospital performed by a single surgeon at a 10-year interval. By comparing 106 patients who underwent ESS in 2003 and 108 patients who underwent ESS in 2013, we investigated changes in ESS in terms of the target group of surgical indications, CT scores, range of operation and complications. RESULTS: With regard to surgical indications, the proportion of patients who underwent surgery due to nasal polyps in 2013 (32.4%) was lower than in 2003 (59.4%), while the proportion of patients undergoing fungal sinusitis surgery in 2013 (13.9%) was higher than in 2003 (0.0%). In terms of preoperative CT evaluation, Lund-Mackay scores for the maxillary sinus, ethmoid sinus, and ostiomeatal unit were lower in 2013 than in 2003. The proportion of ESS performed only in the maxillary sinus in 2013 (20.0%) was higher than in 2003 (10.0%). CONCLUSION: According to this study, the range and extent of sinusitis was favorable in 2013 compared to in 2003. The group of patients requiring treatment for only maxillary sinus disease accounted for a larger proportion of patients in 2013 than in 2003.
Ethmoid Sinus
;
Humans
;
Korea
;
Maxillary Sinus
;
Methods
;
Nasal Polyps
;
Observational Study*
;
Polyps
;
Retrospective Studies*
;
Sinusitis
5.Weaning food practice in children with iron deficiency anemia.
Joo Hee CHANG ; Woo Sik CHEONG ; Yong Hoon JUN ; Soon Ki KIM ; Hung Sik KIM ; Sang Kyu PARK ; Kyung Ha RYU ; Eun Sun YOO ; Chuhl Joo LYU ; Kun soo LEE ; Kwang Chul LEE ; Jae Young LIM ; Du Young CHOI ; Byung Kyu CHOE ; Eun Jin CHOI ; Bong Soon CHOI
Korean Journal of Pediatrics 2009;52(2):159-166
PURPOSE: Iron deficiency anemia (IDA) is one of the most common nutritional deficiencies in children on a weaning diet. We investigated weaning practices in infants and children, as well as their mothers' knowledge about weaning. METHODS: We investigated 129 children with IDA and 166 without IDA (aged 6-36 months) who had visited 10 university hospitals between March 2006 and July 2007. We investigated the hematologic values of both groups. A questionnaire on weaning was answered by the mothers of these children. RESULTS: The hematologic values in the IDA group showed a significant difference from those in the comparison group (P<0.05). Children who were solely breastfed until 6 months of age were 85%, 34% (P<0.05), and weaning was started by 6.3, 6.4 months, respectively (P>0.05). Rice gruel, boiled rice, and fruit juice accounted for approximately 8 0% of the starting foods in both groups (P>0.05). Only 40% of the children in the IDA group had a balanced diet within a month, versus 38% in the comparison group. In response to questions about the necessity of iron-fortified foods for breast-fed infants, less than 50% of mothers in both groups answered correctly. In the IDA group, 42% showed serum ferritin less than 10 ng/ mL, while 92% showed serum MCV less than 72 fL. CONCLUSION: In conclusion, collection of information on history should be thorough for feeding and selective examinations for IDA in high-risk groups. Considering the adaptation period, we suggest beginning children on a weaning diet at 45 months. In addition, we need to educate mothers on weaning practice, especially on the necessity of iron-fortified foods for breast-fed infants.
Anemia, Iron-Deficiency
;
Child
;
Diet
;
Ferritins
;
Fruit
;
Hospitals, University
;
Humans
;
Infant
;
Iron
;
Malnutrition
;
Mothers
;
Surveys and Questionnaires
;
Weaning
6.A Case of Leukemic Pleural Infiltration in Atypical Chronic Myeloid Leukemia.
Hyun Woo KIM ; Sung Sook LEE ; Min Hee RYU ; Jae Lyun LEE ; Heung Moon CHANG ; Tae Won KIM ; Hyun Sook CHI ; Woo Kun KIM ; Jung Shin LEE ; Yoon Koo KANG
Journal of Korean Medical Science 2006;21(5):936-939
Pleural effusion in chronic myeloid leukemia (CML) is poorly understood and rarely reported in the literature. When the pleural effusion is caused by leukemic pleural infiltration, the differential white blood cell count of the effusion is identical to that of the peripheral blood, and the fluid cytology reveals leukemic blasts. We report here a case of bilateral pleural involvement of atypical CML in an 83-yr old male diagnosed with pancreatic cancer with abdominal wall metastasis and incidental peripheral leukocytosis. Based on bone marrow examination, chromosome analysis and polymerase chain reaction he was diagnosed with Philadelphia chromosome negative, BCR/ABL gene rearrangement negative CML. Following 3 months of treatment with gemcitabine for pancreatic cancer, he developed bilateral pleural effusions. All stages of granulocytes and a few blasts were present in both the pleural fluid and a peripheral blood smear. After treatment with hydroxyurea and pleurodesis, the pleural effusion resolved.
Pleural Effusion/*etiology/pathology
;
Male
;
Leukemic Infiltration/*pathology
;
Leukemia, Myeloid, Chronic/complications/*pathology
;
Humans
;
Aged, 80 and over
;
Aged
7.Prevalence and clinical characteristics of microalbuminuria in Koreans: a population-based cross-sectional study.
Eun Ran KIM ; Ki Chul SUNG ; Chang Uk CHON ; Chang Hee KWON ; Young Lyul KOH ; Hyun Jong LEE ; Sung Kun PARK ; Do Young LEE ; Ji Ho YUN ; Byung Jin KIM ; Bum Soo KIM ; Jin Ho KANG ; Man Ho LEE ; Jung Ro PARK ; Seung Ho RYU
Korean Journal of Medicine 2006;70(6):617-626
BACKGROUND: Microalbuminuria (MA) is independent predictor of cardiovascular disease and it cause mortality regardless of the presence of diabetes (DM) and hypertension (HTN). However, few published studies on this topic have been reported in Korea. Therefore, we investigated the MA prevalence and relationship between MA, insulin resistance and cardiovascular risk factor. METHODS: A total of 5,915 (3,053 men and 2,852 women) health screen examinees were enrolled in this study. We measured the anthropometric and biochemical parameters of the atherogenic indexes. RESULTS: The MA prevalence was 7.7% in all participants. The prevalence of MA in the men and women was 9.5% and 5.7%, respectively. Elevated levels of serum fasting glucose, serum fasting insulin, HOMA index, total cholesterols, LDL cholesterol, TG, Body Mass Index (BMI) and the systolic and diastolic blood pressure were significantly associated with MA. The results of multiple logistic regression analysis about MA showed that frequent drinking, low BMI, newly diagnosed DM and elevated levels of HOMA index and blood pressure were significantly associated with MA prevalence. Also, excluding newly diagnosed diabetic and hypertensive subjects, the MA prevalence was 5.7% (6.9% in men, 4.7% in women) and in multiple logistic regression analysis, the MA prevalence significantly increased in the individuals with pre-HTN rather than in the normotensives. CONCLUSIONS: The MA prevalence was 7.7% in all subjects. Except the newly diagnosed diabetic and hypertensive subjects, it was 5.7%. The MA prevalence was significantly increased in the individuals with pre-HTN rather than in the normotensives and MA was related with insulin resistance.
Blood Pressure
;
Body Mass Index
;
Cardiovascular Diseases
;
Cholesterol
;
Cholesterol, LDL
;
Cross-Sectional Studies*
;
Drinking
;
Fasting
;
Female
;
Glucose
;
Humans
;
Hypertension
;
Insulin
;
Insulin Resistance
;
Korea
;
Logistic Models
;
Male
;
Mortality
;
Prehypertension
;
Prevalence*
;
Risk Factors
8.Current Status of Hematopoietic Stem Cell Transplantation in Korean Children.
Dae Chul JEONG ; Hyung Jin KANG ; Hong Hoe KOO ; Hoon KOOK ; Sun Young KIM ; Soon Ki KIM ; Thad GHIM ; Hack Ki KIM ; Hwang Min KIM ; Hyung Nam MOON ; Kyung Duk PARK ; Byung Kiu PARK ; Sang Gyu PARK ; Young Sil PARK ; Hyeon Jin PARK ; Jong Jin SEO ; Ki Woong SUNG ; Hee Young SHIN ; Hyo Sup AHN ; Kun Hee RYU ; Kyung Ha RYU ; Eun Sun YOO ; Chuhl Joo LYU ; Kwang Chul LEE ; Soon Yong LEE ; Young Ho LEE ; Young Tak LIM ; Jae Young LIM ; Pil Sang JANG ; In Sang JEON ; Nak Gyun CHUNG ; Bin CHO ; Jeong Ok HAH ; Pyung Han HWANG ; Tai Ju HWANG
Korean Journal of Hematology 2006;41(4):235-242
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is one of the most important armamentarium against various hematologic malignancies or some solid tumors. We investigated the number of patients who might need transplants and compared with that of actual transplants to conceptualize current status and circumstances of HSCTs in Korean children. METHODS: Questionnaires were sent to Korean Society of Hematopoietic Stem Cell Transplantation (KSHSCT) members who were taking care of children with malignancies or hematologic diseases. Almost all of the newly diagnosed patients between Jan, 1st and Dec, 31st, 2003 were enrolled in the study. RESULTS: Seven hundred forty eight children (male to female ratio = 1.4:1) were enrolled. The median age was 6.1 years old (8 days~28.8 years old). Malignant diseases consisted of 695 cases (92.9%), and among them almost half were hematologic malignancies. The participating members speculated that HSCTs should be indicated in 285 children (38.1%) which included 209 allogeneic, and 76 autologous transplants. In reality, however, allogeneic HSCTs were performed only in 140 children (67.0%) with the median interval of 5.9 month, and autologous transplants in 44 children (57.9%) with 8.3 month. In autologous setting, all the patients received peripheral blood stem cells (PBSCs), whereas bone marrow (61%), cord blood (34%), and PBSC (5%) were used in allogeneic HSCTs. Donor types were as follows: unrelated donor (37%), cord blood (34%), sibling donor (25%), and family (4%). The reasons for not performing HSCTs were unfavorable disease status or death, no availability of suitable donor, economical situation, and refusal by parental preferences. Under the strict insurance regulations, many transplants were not covered by insurance. More autologous transplants were performed without insurance coverage than allogeneic HSCTs (P=0.013). Those cases were advanced cases and HLA mismatch transplants for allogeneic setting, and relatively rare diseases still awaiting favorable results of transplants for autologous setting. CONCLUSION: HSCTs are essential part of treatment strategies for children with various diseases. Unfortunately, however, a third of patients who were in need of transplants did not receive HSCTs due to various reasons. It is necessary to expand unrelated donor pool or cord blood banks for the cases lacking HLA-identical sibling donors. Also medical insurances should cover HSCTs for rare diseases as well as for less favorable but novel situations where there are no suitable alternatives.
Autografts
;
Bone Marrow
;
Child*
;
Disulfiram
;
Female
;
Fetal Blood
;
Hematologic Diseases
;
Hematologic Neoplasms
;
Hematopoietic Stem Cell Transplantation*
;
Hematopoietic Stem Cells*
;
Humans
;
Insurance
;
Insurance Coverage
;
Parents
;
Rare Diseases
;
Siblings
;
Social Control, Formal
;
Stem Cells
;
Tissue Donors
;
Unrelated Donors
;
Surveys and Questionnaires
9.Insidious Onset of Amiodarone Pulmonary Toxicity Presented with Hemoptysis.
Hearn Kook KIM ; Bock Hyun JUNG ; Kun Hee HAN ; Jung Won HWANG ; Young Ju CHO ; Yong Jin PARK ; Hyoung Jung JUNG ; Mi Hye KIM ; Dae Sik RYU ; Gil Hyun KANG
Tuberculosis and Respiratory Diseases 2005;59(4):413-417
Amiodarone is widely used to control fatal arrhythmia. However, amiodarone therapy is associated with a relatively high incidence of pulmonary toxicity, up to 5 to 10%. Typical symptoms are nonspecific and often manifest as nonproductive cough, dyspnea and interstitial infiltrates in patients with acute pneumonitis or chronic fibrosis. However, hemoptysis is a very rare symptom of amiodarone pulmonary toxicity. We report a case of amiodarone pulmonary toxicity, who presented with hemoptysis and was successfully treated with the cessation of amiodarone, with review of the relevant literature.
Amiodarone*
;
Arrhythmias, Cardiac
;
Cough
;
Dyspnea
;
Fibrosis
;
Hemoptysis*
;
Humans
;
Incidence
;
Pneumonia
10.Three Cases Treated with High-dose Cytarabine and Etoposide followed by Autologous Stem Cell Transplantation for Relapsed Primary CNS Lymphoma.
Ja Eun KOO ; Min Hee RYU ; Hee Jeong SHON ; Hye Jin KANG ; Woo Kun KIM ; Cheolwon SUH ; Jung Shin LEE ; Yoon Koo KANG
Korean Journal of Hematology 2005;40(3):172-176
The treatment outcomes with conventional second-line chemotherapy or radiotherapy aregenerally very poor for patients with relapsed primary CNS lymphoma (PCNSL). We treated three relapsed PCNSL patients with high-dose cytarabine plus etoposide (CYVE) chemotherapy, and this was followed by autologous stem cell transplantation (ASCT). The salvage CYVE chemotherapy consisted of cytarabine 2g/m2/d on days 2 to 5 in a 3-hour infusion and 50mg/m2/d on days 1 to 5 in a 12-hourinfusion, and etoposide 200mg/m2/d on days 2 to 5 in a 2-hour infusion. After two cycles of CYVE chemotherapy, two patients achieved a complete response (CR), and one patient achieved a partial response (PR). All three patients experienced febrile neutropenia and grade 4 thrombocytopenia with the CYVE chemotherapy. However, the hematologic toxicities were well managed without any complications. The conditioning regimen for ASCT consisted of BCNU 300mg/m2 on day -7, etoposide 100mg/m2 on days -6 to -3, cytarabine 100mg/m2 on days -6 to -3, and cyclophosphamide 35mg/kg on days -6 to -3 (BEAC). After ASCT, the patient who initially showed a PR with CYVE chemotherapy then achieved a CR. At the time of this report, one patient remained alive in CR for 41 months after CYVE chemotherapy. The remaining two patients experienced relapse 5 months and 4 months after ASCT, respectively, and they ultimately died of disease progression 18 months and 8 months after ASCT, respectively. In our cases, the CYVE chemotherapy+ASCT was well tolerated, and this induced the complete disappearance of the tumor, and one patient showed prolonged disease-free survival. CYVE chemotherapy+ASCT could be a treatment option for relapsed PCNSL.
Anemia, Hemolytic, Autoimmune
;
Carmustine
;
Cyclophosphamide
;
Cytarabine*
;
Disease Progression
;
Disease-Free Survival
;
Drug Therapy
;
Etoposide*
;
Febrile Neutropenia
;
Humans
;
Lymphoma*
;
Radiotherapy
;
Recurrence
;
Stem Cell Transplantation*
;
Stem Cells*
;
Thrombocytopenia
;
Waldenstrom Macroglobulinemia

Result Analysis
Print
Save
E-mail